Tiotropium Bromide Powder for Inhalation — Competitive Intelligence Brief

Tiotropium Bromide Powder for Inhalation (Tiotropium Bromide Powder for Inhalation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic antagonist. Area: Respiratory.

phase 3 Muscarinic antagonist M3 muscarinic receptor Respiratory Small molecule

Target snapshot

Tiotropium Bromide Powder for Inhalation (Tiotropium Bromide Powder for Inhalation) — Henan University of Traditional Chinese Medicine. Tiotropium bromide is a long-acting muscarinic antagonist that works by relaxing the airway muscles to improve breathing in patients with chronic obstructive pulmonary disease (COPD).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tiotropium Bromide Powder for Inhalation TARGET	Tiotropium Bromide Powder for Inhalation	Henan University of Traditional Chinese Medicine	phase 3	Muscarinic antagonist	M3 muscarinic receptor
Atimos®	Atimos®	Chiesi Farmaceutici S.p.A.	marketed	Long-acting muscarinic antagonist (LAMA)	M3 muscarinic receptor
umeclidinium bromide and vilanterol trifenatate	umeclidinium bromide and vilanterol trifenatate	Chiesi Farmaceutici S.p.A.	marketed	Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor and beta-2 adrenergic receptor
Revefenacin 175 µg, Formoterol 20 µg	Revefenacin 175 µg, Formoterol 20 µg	University of Tennessee Graduate School of Medicine	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
albuterol plus tiotropium	albuterol plus tiotropium	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	marketed	Combination bronchodilator (SABA + LAMA)	Beta-2 adrenergic receptor (albuterol); M3 muscarinic receptor (tiotropium)
Aclidinium bromide & formoterol fumarate	Aclidinium bromide & formoterol fumarate	University of Dundee	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
Indacaterol and tiotropium	Indacaterol and tiotropium	University of Dundee	marketed	LABA/LAMA combination bronchodilator	Beta-2 adrenergic receptor and M3 muscarinic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic antagonist class)

1. AstraZeneca · 1 drug in this class
2. Henan University of Traditional Chinese Medicine · 1 drug in this class
3. Novartis · 1 drug in this class